Sansure Biotech Inc(688289) 418 release the annual report of 2021 and the first quarterly report of 2022 at the same time. According to the annual report, the company achieved a revenue of 4.515 billion yuan, a net profit of 2.243 billion yuan and a basic earnings per share of 5.61 yuan in 2021. The company plans to distribute a cash dividend of RMB 3.75 (including tax) for every 10 shares to all shareholders, with a total cash dividend of RMB 148 million (including tax).
In the first quarter of 2022, the company achieved a revenue of 1.44 billion yuan, a year-on-year increase of 23.81%; The net profit was 652 million yuan, a year-on-year increase of 4.78%; The net cash flow from operating activities was 551 million yuan, a year-on-year increase of 79.37%.
strategic production line has a good development momentum
In October 2021, Sansure Biotech Inc(688289) issued the 2021 restricted stock incentive plan (Draft). In order to ensure the incentive effect, Sansure Biotech Inc(688289) set up unique performance assessment indicators, which are divided into strategic production line business income and R & D indicators, and the assessment period spans up to four years. Among them, the business income of strategic production line refers to the elimination of covid-19 virus nucleic acid detection kit, detection service, distribution instrument, technical service, biochemical reagent and distribution reagent business from the company’s revenue, which is an effective indicator to measure the long-term growth of the company’s business in the future; The number of R & D products is an important indicator to measure the company’s future development potential.
The annual report shows that in 2021, Sansure Biotech Inc(688289) the audited strategic production line business income was 758 million yuan, exceeding the target value of the restricted stock incentive plan in 2021 (740 million yuan), laying a foundation for the long-term growth and sustainable development of the company’s future performance.
At the same time, Sansure Biotech Inc(688289) continued to increase investment in R & D, with R & D expenses reaching 188 million yuan in 2021, a year-on-year increase of 126.53%; In the first quarter of 2022, R & D investment increased by 97.64% year-on-year. The company’s R & D strength has been greatly enhanced. In terms of achievements, 132 new products were registered and admitted abroad in 2021, exceeding the R & D indicators of the stock incentive plan.
Sansure Biotech Inc(688289) said that according to the assessment indicators of the stock incentive plan, it is estimated that the business income of the strategic production line will maintain an annual growth rate of more than 30%. The company will take advantage of the advantageous resources accumulated in the early market development to further enhance the in-depth layout of strategic production lines such as respiratory tract, hepatitis, HPV, women and children in the international market.
Industry insiders believe that since December 2021, Sansure Biotech Inc(688289) hpv13 + 2, covid-19 and other strategic products have been listed one after another. The second growth curve of the company is accelerating. With the help of scientific and technological innovation, it may become a new engine of the company in the post epidemic era.
global market accelerated layout
Sansure Biotech Inc(688289) relevant person in charge introduced that since 2021, according to the market demand, the company has immediately adjusted the product structure and supply strategy related to covid-19, and gradually launched “Saint fighter” shelter laboratory, air column tent laboratory and other solutions suitable for different scenarios and needs to meet the needs of the global market.
In 2021, Sansure Biotech Inc(688289) covid-19 nucleic acid detection reagent delivery increased by 135% over the same period of last year, and the cumulative instrument delivery increased by 75% over the same period of last year, which provided strong support for further driving the reagent loading and accelerating the improvement of the market share of the whole line.
Facing the covid-19 detection demand released from the international market, the company further formulated the “5 + 10” overseas strategy based on the “7 + 2” international regional layout in the early stage, and deeply cultivated key countries and regions through the overall solution of covid-19 antigen, antibody + nucleic acid and the mode of localized operation. At present, Sansure Biotech Inc(688289) has prepared to establish subsidiaries in Indonesia, France, the United Kingdom and the Philippines, and set up offices in key countries such as Thailand and Brazil. Through localized operation, it can further explore the local market and businesses in surrounding countries, and further expand the company’s business scope and global influence.
At the same time, Sansure Biotech Inc(688289) relevant person in charge said that for the Chinese market, the company will increase the coverage and strength of cities, districts and counties across the country, and deeply layout strategic production lines such as respiratory tract, hepatitis, HPV, women and children.
Sansure Biotech Inc(688289) relevant person in charge said that the company is fully embarking on a new journey of “secondary entrepreneurship”. On the basis of focusing on its main business, the company will lay out key tracks in the field of in vitro diagnosis, further increase investment in key underlying technologies, key core modules and key raw materials, vigorously improve the accessibility of health services, and develop more convenient, fast, accurate and accessible detection technologies and means that benefit the people, Strive to build a world-class excellent enterprise.
